MapLight Therapeutics GC sells 13,917 shares

MapLight Therapeutics General Counsel Kristopher Hanson reported selling 13,917 shares of Voting Common Stock in open‑market trades.

Rhea-AI Filing Summary

MapLight Therapeutics General Counsel Kristopher Hanson reported selling 13,917 shares of Voting Common Stock in open‑market trades. The sales occurred on May 4, 2026 at weighted average prices, with individual trades ranging from $26.84 to $30.55 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted on December 29, 2025. After the sales, Hanson directly holds 176,248 shares.

Insider Trade Summary 10b5-1

Net Seller: 13,917 shares

Net Sell 4 txns

Insider Hanson Kristopher

Role General Counsel

Sold 13,917 shs ($388K)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock	9,030	$27.50	$248K
Sale	Voting Common Stock	3,908	$28.29	$111K
Sale	Voting Common Stock	296	$29.56	$9K
Sale	Voting Common Stock	683	$30.08	$21K

Holdings After Transaction: Voting Common Stock — 176,248 shares (Direct)

Footnotes (5)

1. F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 13,917 shares Post-sale holdings: 176,248 shares Largest block sale price: $27.50 per share +4 more

7 metrics

Shares sold 13,917 shares Voting Common Stock sold on May 4, 2026

Post-sale holdings 176,248 shares Direct Voting Common Stock held after transactions

Largest block sale price $27.50 per share 9,030-share open-market sale on May 4, 2026

Weighted price range 1 $26.84–$27.835 Weighted average sale price range noted in one footnote

Weighted price range 2 $27.845–$28.73 Weighted average sale price range noted in another footnote

Weighted price range 3 $29.00–$29.9669 Additional weighted average sale price range disclosed

Weighted price range 4 $30.00–$30.55 Highest weighted average sale price range disclosed

Key Terms

Rule 10b5-1 trading plan, weighted average price, Voting Common Stock, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan financial

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Voting Common Stock financial

"security_title: "Voting Common Stock""

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MapLight Therapeutics (MPLT) report for Kristopher Hanson?

MapLight Therapeutics’ General Counsel Kristopher Hanson reported selling 13,917 shares of Voting Common Stock. The Form 4 shows a series of open-market sales on May 4, 2026, executed under a pre-established Rule 10b5-1 trading plan adopted in December 2025.

How many MapLight Therapeutics (MPLT) shares did Kristopher Hanson sell and at what prices?

Kristopher Hanson sold 13,917 shares of MapLight Therapeutics Voting Common Stock. The reported weighted average sale prices for different trade groups ranged between $26.84 and $30.55 per share, reflecting multiple individual transactions within each stated price range on May 4, 2026.

Was Kristopher Hanson’s sale of MPLT shares made under a Rule 10b5-1 plan?

Yes. A footnote states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Kristopher Hanson on December 29, 2025. Such pre-arranged plans schedule trades in advance, indicating the timing of these sales was set before the actual trading date.

How many MapLight Therapeutics (MPLT) shares does Kristopher Hanson hold after the reported sales?

Following the reported open-market sales, Kristopher Hanson directly holds 176,248 shares of MapLight Therapeutics Voting Common Stock. This post-transaction holding figure is provided in the Form 4 and reflects his remaining direct ownership after the 13,917 shares were sold.

Why do the MPLT Form 4 footnotes mention weighted average sale prices and price ranges?

The footnotes explain that each reported sale price is a weighted average of multiple trades within specified ranges. For example, some shares were sold between $26.84 and $27.835. The insider offers to provide full trade-by-trade pricing details to the company, shareholders, or SEC staff upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 08:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanson Kristopher

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	05/04/2026		S(1)		9,030	D	$27.5(2)	181,135	D
Voting Common Stock	05/04/2026		S(1)		3,908	D	$28.29(3)	177,227	D
Voting Common Stock	05/04/2026		S(1)		296	D	$29.56(4)	176,931	D
Voting Common Stock	05/04/2026		S(1)		683	D	$30.08(5)	176,248	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Kristopher L. Hanson	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)